RBOT: NYSE Warrants Listed with $11.50 Exercise Price

Rhea-AI Filing Summary

Vicarious Surgical Inc. filed an 8-K reporting a material event dated September 12, 2025. The filing lists corporate identifiers and contact details and shows trading symbols RBOT and RBOT WS on the New York Stock Exchange. It discloses warrants exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share. The form is signed by Stephen From, Chief Executive Officer. The filing contains limited narrative or financial detail beyond the warrant description and administrative information.

Positive

• Warrants listed on the New York Stock Exchange (symbols RBOT and RBOT WS) provide public price discovery
• Clear exercise price disclosed at $11.50 per share, giving holders a defined conversion benchmark

Negative

• Material warrant terms are missing (expiration date, adjustment provisions, issuance date), limiting immediate investor assessment
• No financial or dilution impact information (no share count, potential proceeds, or effect on outstanding shares) is provided

Insights

Equity Capital Markets Analyst

Warrant listing and exercise price are the key market signals.

The filing shows listed warrants (RBOT WS) tied to Class A common stock with an exercise price of $11.50, which establishes a concrete conversion reference for holders and market makers. That exercise price is a fixed numeric benchmark for potential future equity issuance if warrants are exercised.

Primary dependencies include actual warrant trading volume, expiration dates, and any anti-dilution or adjustment provisions not disclosed here. Watch for subsequent filings or exchange notices that provide warrant terms, expiration dates, or effects on diluted share count within several weeks.

Corporate Secretary / SEC Filings Specialist

The 8-K is largely administrative; missing term details limit investor assessment.

The document provides issuer identifiers, signatory, and the existence of NYSE-listed warrants and the related exercise price. It does not include material terms such as issuance date, expiration date, conversion ratio beyond one share, or any cashless exercise mechanics, which are normally material for valuation and dilution analysis.

Expect follow-up disclosures or exhibits to clarify warrant terms and potential equity impact; if none appear, investors should treat the current filing as incomplete for fully gauging dilution and timing effects over the near term.

false 0001812173 0001812173 2025-09-12 2025-09-12 0001812173 RBOT:ClassCommonStockParValue0.0001PerShareMember 2025-09-12 2025-09-12 0001812173 RBOT:WarrantsToPurchaseOneShareOfClassCommonStockEachAtExercisePriceOf11.50PerShareMember 2025-09-12 2025-09-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2025

VICARIOUS SURGICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39384		87-2678169
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

78 Fourth Avenue
Waltham, Massachusetts		02451
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 868-1700

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, par value $0.0001 per share		RBOT		The New York Stock Exchange
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share		RBOT WS		The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 12, 2025 (the “Effective Date”), Donald Tang resigned as a member of the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”), effective as of the Effective Date. Mr. Tang’s resignation did not result from any disagreement regarding the Company’s operations, policies or practices. In connection with Mr. Tang’s resignation, the Board appointed Victoria Carr-Brendel as a member of the Audit Committee of the Board.

1 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VICARIOUS SURGICAL INC.
	By:	/s/ Stephen From
	Name:	Stephen From
	Title:	Chief Executive Officer

Date: September 16, 2025

2

FAQ

What did Vicarious Surgical (RBOT) disclose in the 8-K dated September 12, 2025?

The company disclosed NYSE trading symbols RBOT and RBOT WS and that warrants are exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share.

Does the filing state the warrants' expiration date for RBOT WS?

No. The filing does not provide an expiration date or other timing details for the warrants.

Will the warrants cause dilution if exercised?

Potentially yes if exercised, but the filing does not disclose the number of warrants outstanding or the resulting diluted share count.

Who signed the 8-K for Vicarious Surgical?

The form is signed by Stephen From, identified as Chief Executive Officer.

Where are the warrants listed?

The warrants are listed on the New York Stock Exchange under the symbol RBOT WS.